Analytical Data
-
基因名
HLA-A*02:01&B2M&Glypican 3(FVGEFFTDV) Monomer
- Application
-
别名
HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&FVGEFFTDV
-
分子量
42-45 kDa and 14 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is a widely studied human leukocyte antigen known for its critical role in the immune response, specifically in the presentation of peptide antigens to T cells. It is commonly associated with various diseases, including cancers and viral infections. In this context, the glypican-3 (GPC3) protein, particularly the peptide FVGEFFTDV derived from it, has gained attention as a tumor-associated antigen. GPC3 is overexpressed in several malignancies, particularly in hepatocellular carcinoma, making it a promising target for immunotherapy. The recombinant protein consisting of HLA-A*02:01, beta-2 microglobulin (B2M), and the GPC3 peptide FVGEFFTDV is being investigated to facilitate the understanding of T cell responses and to potentially enhance the development of novel cancer vaccines. This research aims to elucidate the structural and functional aspects of the peptide-MHC (Major Histocompatibility Complex) interaction, which is crucial for T cell recognition and activation. Understanding these interactions at the molecular level could pave the way for effective immunotherapeutic strategies targeting tumors expressing GPC3, ultimately contributing to improved treatment options for patients suffering from GPC3-positive cancers.
